Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365
Senseonics (NYSE American: SENS) announced a significant strategic shift in its Eversense 365 commercialization strategy. The company has signed a Memorandum of Understanding to take over all global commercialization and distribution from Ascensia Diabetes Care, effective January 1, 2026.
Key developments include the appointment of Brian Hansen as Chief Commercial Officer and an expanded debt facility up to $100 million with Hercules Capital to fund the commercial organization. The company expects 2025 global net revenue of $34-38 million and projects gross margin expansion to 50% in 2026, increasing to over 70% at scale.
For 2025, Senseonics anticipates doubling its global patient base, with gross margins between 32.5% and 37.5%. Cash used in operations is expected to be approximately $60 million.
Senseonics (NYSE American: SENS) ha annunciato un cambiamento strategico importante nella commercializzazione dell'Eversense 365. L'azienda ha firmato un Memorandum of Understanding per assumere la responsabilit脿 globale di commercializzazione e distribuzione da Ascensia Diabetes Care, a partire dal 1掳 gennaio 2026.
Tra le novit脿 principali c'猫 la nomina di Brian Hansen a Chief Commercial Officer e un ampliamento della linea di credito fino a 100 milioni di dollari con Hercules Capital per finanziare l'organizzazione commerciale. Senseonics prevede ricavi netti globali 2025 pari a 34-38 milioni di dollari e stima un'espansione del margine lordo al 50% nel 2026, con oltre il 70% una volta raggiunta la scala operativa.
Per il 2025 Senseonics si aspetta di raddoppiare la propria base pazienti globale, con margini lordi compresi tra il 32,5% e il 37,5%. L'utilizzo di cassa per le operazioni 猫 stimato intorno ai 60 milioni di dollari.
Senseonics (NYSE American: SENS) anunci贸 un cambio estrat茅gico relevante en la comercializaci贸n del Eversense 365. La compa帽铆a firm贸 un Memorando de Entendimiento para asumir la comercializaci贸n y distribuci贸n globales de Ascensia Diabetes Care, con efecto a partir del 1 de enero de 2026.
Entre los desarrollos clave figura la designaci贸n de Brian Hansen como Chief Commercial Officer y una l铆nea de deuda ampliada hasta 100 millones de d贸lares con Hercules Capital para financiar la organizaci贸n comercial. La compa帽铆a espera ingresos netos globales en 2025 de 34-38 millones de d贸lares y proyecta que el margen bruto aumente al 50% en 2026, superando el 70% a escala.
Para 2025, Senseonics anticipa duplicar su base de pacientes global, con m谩rgenes brutos entre el 32,5% y el 37,5%. El efectivo utilizado en operaciones se estima en aproximadamente 60 millones de d贸lares.
Senseonics (NYSE American: SENS)電� Eversense 365 靸侅毄頇� 鞝勲灥鞐愳劀 欷戨寑頃� 鞝勴櫂鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 2026雲� 1鞗� 1鞚茧秬搿� Ascensia Diabetes Care搿滊秬韯� 旮�搿滊矊 靸侅毄頇� 氚� 鞙犿喌 鞝勱秾鞚� 鞚胳垬頃橁赴搿� 頃橂姅 鞏戫暣臧侅劀(MOU)毳� 觳搓舶頄堨姷雼堧嫟.
欤检殧 雮挫毄鞙茧電� Brian Hansen鞚� Chief Commercial Officer搿� 鞛勲獏頃橁碃, 靸侅梾 臁办 鞛愱笀 臁半嫭鞚� 鞙勴暣 Hercules Capital瓿� 斓滊寑 1鞏� 雼煬鞚� 頇曤寑霅� 攵�毂� 鞁滌劋鞚� 觳搓舶頃� 鞝愳澊 韽暔霅╇媹雼�. 須岇偓電� 2025雲� 鞝� 靹戈硠 靾滊Г於滌潉 3,400毵寏3,800毵� 雼煬搿� 鞓堨儊頃橂┌, 2026雲勳棎電� 毵れ稖齑濎澊鞚惦鞚� 50%搿� 頇曤寑霅橁碃, 攴滊臧� 旎れ氅� 70%毳� 齑堦臣頃� 瓴冹溂搿� 鞝勲頃╇媹雼�.
2025雲勳棎電� Senseonics臧� 鞝� 靹戈硠 頇橃瀽 靾橂ゼ 霊� 氚半 電橂Υ 瓴�鞙茧 旮半寑頃橂┌, 毵れ稖齑濎澊鞚惦鞚� 32.5%~37.5% 氩旍渼搿� 氤搓碃 鞛堨姷雼堧嫟. 鞓侅梾頇滊彊鞐� 靷毄霅橂姅 順勱笀鞚� 鞎� 6,000毵� 雼煬臧� 霅� 瓴冹溂搿� 鞓堨儊霅╇媹雼�.
Senseonics (NYSE American: SENS) a annonc茅 un changement strat茅gique majeur dans sa strat茅gie de commercialisation de l'Eversense 365. La soci茅t茅 a sign茅 un protocole d'accord pour reprendre l'ensemble de la commercialisation et de la distribution mondiales d'Ascensia Diabetes Care, 脿 compter du 1er janvier 2026.
Parmi les 茅volutions cl茅s figurent la nomination de Brian Hansen au poste de Chief Commercial Officer et une facilit茅 d'endettement 茅largie jusqu'脿 100 millions de dollars avec Hercules Capital pour financer l'organisation commerciale. La soci茅t茅 pr茅voit un chiffre d'affaires net mondial 2025 de 34 脿 38 millions de dollars et estime une expansion de la marge brute 脿 50 % en 2026, au-del脿 de 70 % 脿 grande 茅chelle.
Pour 2025, Senseonics anticipe le doublement de sa base de patients mondiale, avec des marges brutes comprises entre 32,5 % et 37,5 %. Les flux de tr茅sorerie utilis茅s par les op茅rations devraient s'茅lever 脿 environ 60 millions de dollars.
Senseonics (NYSE American: SENS) hat eine bedeutende strategische Neuausrichtung seiner Eversense-365-Kommerzialisierungsstrategie bekannt gegeben. Das Unternehmen hat ein Memorandum of Understanding unterzeichnet, um ab dem 1. Januar 2026 weltweit die Kommerzialisierung und den Vertrieb von Ascensia Diabetes Care zu 眉bernehmen.
Wesentliche Entwicklungen sind die Ernennung von Brian Hansen zum Chief Commercial Officer sowie eine erweiterte Fremdfinanzierung von bis zu 100 Mio. USD mit Hercules Capital zur Finanzierung der Vertriebsorganisation. Das Unternehmen erwartet globale Nettoums盲tze f眉r 2025 in H枚he von 34鈥�38 Mio. USD und prognostiziert eine Ausweitung der Bruttomarge auf 50 % im Jahr 2026, mit mehr als 70 % bei skalierter Gesch盲ftst盲tigkeit.
F眉r 2025 rechnet Senseonics damit, seine globale Patientenbasis zu verdoppeln, mit Bruttomargen zwischen 32,5 % und 37,5 %. Der operative Mittelabfluss wird auf etwa 60 Mio. USD gesch盲tzt.
- Gross margin expected to expand to 50% in 2026 and over 70% at scale
- Projected doubling of global patient base during 2025
- Secured up to $100 million non-dilutive debt facility with Hercules Capital
- Expected immediate revenue improvement through direct commercialization
- Appointment of experienced industry executive Brian Hansen as CCO
- Significant cash burn with $60 million expected to be used in operations for 2025
- Current gross margins remain relatively low at 32.5-37.5% for 2025
- Substantial investment required to build commercial infrastructure
- Operational risks associated with transitioning from partnership model to direct sales
Insights
Senseonics taking over Eversense commercialization from Ascensia will boost revenues and margins while enabling more agile market response.
This strategic move by Senseonics to bring the Eversense 365 commercialization in-house represents a significant shift in business strategy that could substantially improve financial performance. By taking direct control of global sales and marketing from Ascensia Diabetes Care after their 5-year partnership, Senseonics is positioned to eliminate revenue sharing costs and capture the full value of each sale.
The company projects an immediate gross margin expansion to 50% in 2026, with potential growth beyond 70% at scale - a dramatic improvement from their current 2025 guidance of 32.5-37.5%. This vertical integration should address the growing divergence between Eversense's market needs and Ascensia's core blood glucose monitoring business.
The $100 million expanded debt facility with Hercules Capital provides non-dilutive funding to build out the commercial infrastructure, which is crucial as the company attempts to scale operations without issuing additional equity. Bringing aboard Brian Hansen as CCO adds experienced leadership, as he previously served as Chief Commercial Officer at Tandem Diabetes Care and has been leading Ascensia's CGM division.
For 2025, Senseonics maintains its revenue guidance of $34-38 million, expecting to double its global patient base with revenue weighted toward the second half of the year. The transitional timeline is structured, with U.S. operations transferring January 2026 and international markets following with transition service agreements.
The strategic rationale centers on Eversense 365 - the first and only year-long CGM - being at an inflection point requiring dedicated commercial focus and investment. By controlling the entire value chain, Senseonics should be able to respond more quickly to market needs and accelerate adoption of this differentiated technology in the competitive CGM space.
CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics
Brian Hansen to be appointed Chief Commercial Officer
Non-dilutive debt facility expanded up to
Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time
GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distribution of Eversense 365 and future products from Ascensia Diabetes Care, a member of PHC Group, to Senseonics.
Since 2020, Ascensia has held the exclusive worldwide distribution rights for Eversense products, including Eversense 365. Under the terms of the Memorandum of Understanding, Senseonics would assume responsibility for all global sales, marketing and commercialization in the U.S. beginning January 1, 2026, and utilize Transition Service Agreements through Ascensia until fully established in markets outside the U.S. Brian Hansen, President of CGM at Ascensia since February 2024 and former Chief Commercial Officer at Tandem Diabetes Care, would join Senseonics as Chief Commercial Officer on January 1, 2026. The companies are currently working together to develop definitive documentation for the planned transaction.
As awareness of Eversense continues to grow with the momentum of the Eversense 365 approval, the go-to-market approach is increasingly diverging from Ascensia鈥檚 core blood glucose monitoring business. Eversense is at an inflection point that requires strategic investment and fully-dedicated commercial efforts, along with tight vertical integration to quickly respond to market needs. By unifying the Eversense business and incorporating commercial activities directly within Senseonics, the companies believe Eversense would achieve accelerated growth and realize its full potential faster than under the current structure.
Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics stated, 鈥淚鈥檓 thrilled to bring Eversense 365 commercialization back in-house and directly control investment in growing the brand to better serve the needs of patients and providers. With Brian to remain at the helm of Senseonics鈥� commercialization efforts, we are confident that this move will yield benefits for our customers and our shareholders. Eversense 365 is the world鈥檚 first and only year-long continuous glucose monitor, deserving a dedicated sales force and commercial infrastructure. We truly appreciate the partnership and investment that PHC Group and Ascensia has made in Senseonics. We look forward to welcoming the talented commercial team to Senseonics to help ensure a positive experience for our customers, while working to accelerate growth of Eversense 365.鈥�
Koichiro Sato, Chief Operating Officer and Chief Strategy Officer of PHC Group and CEO of Ascensia Diabetes Care, commented: 鈥淲e are very proud to have worked with Senseonics on commercializing Eversense and are committed to supporting Senseonics in establishing their own commercial operations and smoothly transitioning to them under the planned agreements. The Eversense long-term CGM system can help overcome many frustrations in diabetes management and we believe in the growth potential of Eversense and remain invested in Senseonics.鈥�
For Senseonics, bringing Eversense commercial sales and operations in-house as planned should position the company to better meet payer, provider and patient needs, as well as improve efficiency and agility. Owning the commercial channel is also expected to increase topline revenue and expand margins by eliminating Ascensia revenue sharing. The investments in the commercial organization would be funded in part by improved margins, but also from the expanded
Full Year 2025 Financial Outlook
Senseonics continues to expect full-year 2025 global net revenue to be approximately
Conference Call Details
Management will host an investor call and live webcast to discuss the commercial transition starting at聽8:00 a.m. (Eastern Time), September 4, 2025.
The link to the webcast will be available on聽Senseonics Holdings, Inc.聽website at聽聽by navigating to 鈥淚nvestor Relations,鈥� and then 鈥淓vents & Publications,鈥� and will be archived there for future reference. To listen to the conference call, please dial 1-800-579-2543 (US/Canada) or 1-785-424-1789 (International), passcode SENSE365, approximately ten to five minutes prior to start time.
础产辞耻迟听厂别苍蝉别辞苍颈肠蝉
Senseonics Holdings, Inc.聽("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology.聽Senseonics'聽CGM systems Eversense庐聽365 and Eversense庐聽E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
About Eversense
The Eversense庐聽Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense庐聽365 and 180 days for Eversense庐聽E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense庐聽365 and one time per day after day 21 for Eversense庐聽E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see聽.
Forward Looking Statements
Any statements in this press release about the expectations regarding the transition of the commercialization responsibility of Eversense 365 from Ascensia to Senseonics, the finalization of definitive documentation for such transition, the smooth transition of the commercial team and operations, the success of the future commercialization of Eversense 365, the financial implications of the transition, including revenue and gross margin projections, and the availability of improved margins to support certain investments, trends of interest in, and market acceptance and adoption of, Eversense 365 by patients and prescribers, revenue expectations, product development plans and/or growth of Eversense, the appointment of Mr. Hansen to serve as the Company鈥檚 chief commercial officer, the availability of future borrowing under the Hercules debt facility, the expectations for the facility鈥檚 coverage of costs, the revenue, gross margin, cash flow and global installed customer base projections, and global installed customer base and reorder assumptions, under the heading 鈥淔ull Year 2025 Financial Outlook,鈥� and other statements containing the words "believe," 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減rojects,鈥� 鈥渨ill,鈥� 鈥減lanned,鈥� and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including:鈥� uncertainties inherent in the negotiation and finalization of the transition agreements with Ascensia, uncertainties in connection with the transition of the commercial organization from Ascensia to Senseonics, risk related to the ongoing commercialization of Eversense 365, uncertainties in prescriber and patient decisions and responses to new technology or initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration of new technology, uncertainties in the development of and competition in the overall CGM market, uncertainties with respect to satisfying conditions to the availability of borrowing capacity under the Company鈥檚 amended credit facility with Hercules, the potential inability to receive requisite stockholder approval of the Company鈥檚 recently proposed reverse stock split, and such other factors as are set forth in the risk factors detailed in鈥疭enseonics'鈥疉nnual Report on Form 10-K for the year ended鈥疍ecember 31, 2024鈥痑nd subsequent quarterly reports on Form 10-Q filed with the鈥疭EC鈥痷nder the heading "Risk Factors" and the Definitive Proxy Statement filed with the鈥疭EC鈥痮n August 18, 2025鈥痷nder the heading 鈥淐ertain Risks and Potential Disadvantages Associated with a Reverse Stock Split.鈥� In addition, the forward-looking statements included in this press release represent Senseonics鈥� views as of the date hereof.鈥疭enseonics鈥痑nticipates that subsequent events and developments will cause Senseonics鈥� views to change. However, while鈥疭enseonics鈥痬ay elect to update these forward-looking statements at some point in the future,鈥疭enseonics鈥痵pecifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics鈥� views as of any date subsequent to the date hereof.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
FAQ
What are the key terms of Senseonics' new commercialization agreement for Eversense 365?
What is SENS stock's revenue guidance for 2025?
How will the commercialization transition affect Senseonics' gross margins?
Who is Brian Hansen and what will be his role at Senseonics (SENS)?
How is Senseonics funding the commercial organization expansion?
